Testosterone Sold as SARMs: What the Paradigm Peptides Case Reveals About Unverified Sourcing

Of everything in the federal case against Paradigm Peptides, one finding stands out: the adulteration was not a trace-contamination problem. It was substitution: customers ordered one substance and received another, with no indication on the label, the certificate of analysis, or the product page. Understanding how that happens, and why it went undetected across 54,000 customers, is the most useful thing anyone sourcing research compounds can take away from this case.

What was actually in Paradigm Peptides products?

According to the Department of Justice, Paradigm Peptides imported its inventory from suppliers in China, India, and other countries and sold it without testing. The products were marketed as domestically manufactured and FDA-approved. Both claims were false.

When federal investigators subjected the catalog to laboratory analysis, the results included six mislabeled SARM products containing testosterone. Victim reports collected in the case describe the downstream consequences: severe cystic acne, suppression of natural testosterone production severe enough to require hormone replacement therapy, cardiac issues, and psychiatric effects up to and including steroid-induced psychosis and suicidal ideation.

The reason those harms were so severe is precisely that the substitution was invisible. A person handling what they believe is a nonsteroidal compound has no reason to anticipate the endocrine effects of an actual steroid hormone. The label was not just wrong; it actively pointed away from the truth.

Why does adulteration happen in gray-market supply chains?

Substitution of this kind is usually an economics problem before it is an ethics problem. Bulk testosterone is cheap and abundant. Many SARMs are more expensive to synthesize, subject to variable overseas quality, and intermittently hard to source. An upstream manufacturer that ships testosterone in a bag labeled as a SARM cuts costs invisibly, unless someone downstream tests it.

That is the critical failure point: somebody in the chain has to test. A reseller that imports finished powders and never verifies identity is not really a supplier in any meaningful sense. It is a forwarding service for whatever an overseas factory decided to put in the bag. Paradigm's five-year run demonstrates that the absence of testing is not self-correcting; customers cannot taste the difference, and the harm reports arrive long after the revenue does.

What testing detects a substituted compound?

The Paradigm substitutions would have been caught by the most basic identity testing that reputable suppliers commission on every batch. Three layers matter:

Mass spectrometry (identity). MS confirms that the molecule in the vial has the molecular weight of the labeled compound. Testosterone and the SARMs it was substituted for are entirely different molecules; MS distinguishes them immediately. This is the single test that would have unraveled Paradigm's catalog on day one.

HPLC (purity). High-performance liquid chromatography quantifies what fraction of the sample is the target compound versus impurities, degradation products, or unrelated substances. A ≥99% purity claim is only meaningful when it is backed by an actual chromatogram on a batch-specific certificate of analysis. Note that purity alone cannot catch substitution: a vial can be 99% pure and 100% the wrong molecule.

Endotoxin and sterility testing. For research compounds handled in laboratory settings, endotoxin contamination is a separate axis of risk from chemical identity, and it is invisible to both MS and HPLC.

Equally important is who runs the tests. In-house numbers from the same party selling the product are a claim, not a verification. Independent third-party laboratories, identified by name on the certificate of analysis so the document can be confirmed with the lab directly, are the difference between marketing copy and evidence.

What red flags did the Paradigm case put on record?

The federal record reads like a checklist of warning signs, all of which were visible to the public before the indictment:

"FDA-approved" claims. Research peptides and SARMs are not FDA-approved products. A supplier making that claim is either ignorant of the regulatory landscape or lying about it; both are disqualifying.

"Made in the USA" without evidence. Paradigm's inventory was imported. Domestic-manufacturing claims are only as good as the documentation behind them: a named facility, not a flag icon on a product page.

No batch-specific documentation. A generic quality statement that never changes between lots is not a certificate of analysis. Every batch is a separate manufacturing event and a separate opportunity for substitution.

Ignored regulatory warnings. The FDA sent Paradigm warning letters in 2020 and again in 2022, public documents searchable in the FDA's warning letter database, and the company kept selling for years afterward. Checking that database takes two minutes and would have flagged Paradigm to any customer who looked.

The structural lesson

At sentencing, Judge Cristal Brisco described "an incredible trail of harm." The mechanism of that harm was informational: 54,000 customers made decisions based on labels, and the labels were false. In a market segment without pre-market regulation, documentation is the entire safety system. When a supplier fabricates it, there is nothing underneath.

That is not an argument that the research peptide market cannot be navigated. It is an argument that verification has to be treated as the product. Purity numbers, identity confirmation, named third-party labs, batch traceability: these are not marketing differentiators. As the Paradigm case shows, they are the only thing separating a labeled vial from an unlabeled one.

For a practical walkthrough of how to run that verification on any supplier, including how to read a COA and confirm it with the issuing lab, see our guide: How to vet a research peptide supplier before you order. For the full case history, see What happened to Paradigm Peptides.

Frequently asked questions

What did lab testing find in Paradigm Peptides products?

Federal testing found that six products sold as testosterone-mimicking SARMs contained actual testosterone, a Schedule III controlled anabolic steroid, rather than the labeled compounds. The inventory was imported and sold without testing.

Can a certificate of analysis detect a substituted compound?

Only if it includes identity testing. Mass spectrometry confirms the molecule matches the label; HPLC purity numbers alone cannot catch substitution, because a sample can be highly pure and still be the wrong substance.

Are SARMs FDA-approved?

No. No SARM is an FDA-approved drug, and the FDA has publicly warned about risks associated with SARM products. Any supplier claiming FDA approval for SARMs or research peptides is misrepresenting them.

Why didn't customers notice the testosterone substitution?

Substitution is undetectable without laboratory analysis. Customers relied on labels and marketing that falsely claimed domestic manufacture and FDA approval; the physical products offered no visible indication of what they contained.

All products sold by Blackwell BioLabs are for research use only. Nothing in this article is medical advice or a recommendation for human use of any compound discussed.

Sources:

• U.S. Department of Justice, Northern District of Indiana, sentencing press release
• CBS News: "Judge sentences peptide vendor to nearly 6 years in prison for 'an incredible trail of harm'"